---
title: "Zepbound (tirzepatide), all indications: Pharmacology questions"
description: "Pharmacology questions on Zepbound (tirzepatide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pharmacokinetics and Components. Questions: What is the half-life of Zepbound? How is Zepbound metabolized and eliminated? What are the inactive ingredients in Zepbound? 3 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/zepbound/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Zepbound (tirzepatide), all indications: Pharmacology questions

Manufacturer: Lilly USA, LLC  
Prescribing information: [Zepbound](https://uspl.lilly.com/zepbound/zepbound.html#pi)  
Indication pages: [Chronic weight management](https://www.evicenter.com/medical-information/zepbound--chronic-weight-management)

## Pharmacokinetics

<a id="zepbound-half-life"></a>

### What is the half-life of Zepbound?

> “The elimination half-life is approximately 5-6 days in patients with overweight or obesity, and in patients with OSA and obesity.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=The%20elimination%20half%2Dlife%20is%20approximately,patients%20with%20OSA%20and%20obesity.)

> “Steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Steady%2Dstate%20plasma%20tirzepatide%20concentrations%20were,weeks%20of%20once%20weekly%20administration.)

> “Following subcutaneous administration, the median time (range) to maximum plasma concentration of tirzepatide is 24 hours (8 to 72 hours). The mean absolute bioavailability of tirzepatide following subcutaneous administration is 80%. Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Following%20subcutaneous%20administration%2C%20the%20median,abdomen%2C%20thigh%2C%20or%20upper%20arm.)

<a id="zepbound-metabolism"></a>

### How is Zepbound metabolized and eliminated?

> “Metabolism
>
> Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid, and amide hydrolysis.
>
> Excretion
>
> The primary excretion routes of tirzepatide metabolites are via urine and feces. Intact tirzepatide is not observed in urine or feces.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Metabolism,observed%20in%20urine%20or%20feces.)

## Components

<a id="zepbound-inactive-ingredients"></a>

### What are the inactive ingredients in Zepbound?

> “Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Each multi-dose vial or single-patient-use KwikPen contains 2.4 mL of solution, which provides 4 doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide per 0.6 mL. Each dose contains the following excipients: benzyl alcohol (5.4 mg), glycerin (4.8 mg), phenol (1.08 mg), sodium chloride (1.05 mg), sodium phosphate dibasic heptahydrate (0.8 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. ZEPBOUND has a pH of 6.5 to 7.5.”

Source: [ZEPBOUND: Prescribing information, captured 2026-11-12](https://uspl.lilly.com/zepbound/zepbound.html#pi:~:text=Each%20single%2Ddose%20pen%20or%20single%2Ddose,pH%20of%206.5%20to%207.5.)

## Related pages
- [Medical information: Zepbound (tirzepatide): All indications](https://www.evicenter.com/medical-information/zepbound)
- [Indication](https://www.evicenter.com/medical-information/zepbound/indication)
- [Safety](https://www.evicenter.com/medical-information/zepbound/safety)
- [Specific populations](https://www.evicenter.com/medical-information/zepbound/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/zepbound/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/zepbound/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/zepbound/storage-and-supply)
